Results 11 to 20 of about 926 (182)

Peroxisome Proliferator‐Activated Receptor (PPAR) Agonists for Patients With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid (UDCA): A Systematic Review and Meta‐Analysis of Randomized Controlled Trials [PDF]

JGH Open
Objective Peroxisome proliferator‐activated receptor (PPAR) agonists are agents used for patients with primary biliary cholangitis (PBC) who do not respond to conventional agents like ursodeoxycholic acid (UDCA).
Maadeha H. Zaidi, Zaroon Haider, FNU Sadia, Muhammad Tayyab, Muhammad Naveed Tariq, Hasaan H. Ans, Muhammad Bilal Javaid, Ahmad Khan, Muhammad Hassan Ahmad, Rahman Rasheed, Uzair Jafar, Huzaifa Ahmad Cheema, Asma'a Munasar Ali Alsubari, Muhammad Shahzil, Essam Rashad, Rehmat Ullah Awan, Hassam Ali, Prasun K. Jalal   +17 more
doaj   +3 more sources

Efficacy and Safety of Novel Oral Anti-Cholestatic Agents for Primary Biliary Cholangitis: Meta-Analyses and Systematic Review [PDF]

Pharmaceuticals
Background: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive bile duct damage and cholestasis. While ursodeoxycholic acid (UDCA) is the first-line therapy, approximately 40% of patients have incomplete ...
Eyad Gadour, Bogdan Miutescu, Hiba Bashir, Abubaker Ali, Salem Alanzi, Abdullah A. Al-Shahrani, Aymen Almuhaidb, Shahed Mohamed, Faisal Abaalkhail, Hadi Kuriry, Mohammed Saad AlQahtani   +10 more
doaj   +3 more sources

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence

Diabetes, Metabolic Syndrome and Obesity, 2015
Aravind Sosale,1 Banshi Saboo,2 Bhavana Sosale11Diacon Hospital, Bangalore, 2Dia Care (Diabetes Care and Hormone Clinic), Ahmedabad, IndiaAbstract: Diabetes mellitus (DM) is one of the most dreaded metabolic disorders in the world today.
Sosale A, Saboo B, Sosale B
doaj   +6 more sources

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial

Journal of Lipid Research, 2022
Saroglitazar, being a dual PPAR-α/γ agonist, has shown beneficial effect in diabetic dyslipidemia and hypertriglyceridemia. Fibrates are commonly used to treat severe hypertriglyceridemia.
Rene Rodriguez-Gutierrez, Jose Gerardo González, Deven Parmar, Farheen. Shaikh, Pio Cruz-López   +4 more
doaj   +2 more sources

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.

PLoS ONE, 2022
Background and objectiveSaroglitazar is a newer antidiabetic agent approved to manage dyslipidemia. The objective is tevaluate the efficacy and safety profiles of saroglitazar in patients with dyslipidemia.MethodsA systematic search was conducted using ...
Manik Chhabra, Kota Vidyasagar, Sai Krishna Gudi, Jatin Sharma, Rishabh Sharma, Muhammed Rashid   +5 more
doaj   +2 more sources

Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet

BMC Cancer, 2023
Background Saroglitazar is a novel PPAR-α/γ agonist with predominant PPAR-α activity. In various preclinical models, saroglitazar has been shown to prevent & reverse symptoms of NASH. In view of these observations, and the fact that NASH is a progressive
Suresh R. Giri, Bibhuti Bhoi, Chitrang Trivedi, Akshyaya Rath, Rohan Rathod, Anish Sharma, Ramchandra Ranvir, Shekhar Kadam, Kailash Ingale, Hiren Patel, Abraham Nyska, Mukul R. Jain   +11 more
doaj   +2 more sources

The First Approved Agent in the Glitazar’s Class: Saroglitazar

Current Drug Targets, 2014
The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the treatment of Type II diabetes. Saroglitazar is marketed under the trade name Lipaglyn, developed by the Zydus Cadila. Lipaglyn is the first indigenously developed NCE by any Indian pharmaceutical company, ever. Lipaglyn has been
Beda Durga Prasad, A. Srinivas Rao, Mondra Sreekanth, Sheelam Sumathi, Sreenivas Pasula, Vadlamudi Naga Ratna Sai   +5 more
core   +6 more sources

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Scientific Reports, 2020
Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of nonalcoholic steatohepatitis (NASH). We tested the hypothesis that saroglitazar, a PPAR α/γ agonist would improve NASH in the diet-induced animal model of NAFLD ...
Divya P. Kumar, Rebecca Caffrey, Jonathon Marioneaux, Prasanna K. Santhekadur, Madhavi Bhat, Cristina Alonso, Srinivas V. Koduru, Binu Philip, Mukul R. Jain, Suresh R. Giri, Pierre Bedossa, Arun J. Sanyal   +11 more
doaj   +2 more sources

Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience

Case Reports in Medicine, 2020
Background. Diabetes and other metabolic abnormalities including high triglycerides (TGs) are commonly seen comorbid conditions in patients having nonalcoholic fatty liver disease (NAFLD).
Sayak Roy
doaj   +2 more sources

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment. [PDF]

Clin Pharmacol Ther
Saroglitazar magnesium, a dual PPAR α/γ agonist, currently in Phase III for treating primary biliary cholangitis (PBC), was evaluated for its pharmacokinetic (PK) profile, safety, and pharmacodynamics in participants with cholestatic liver disease (CLD ...
Vuppalanchi R, Cruz MM, Momin T, Shaikh F, Swint K, Patel H, Parmar D.   +6 more
europepmc   +3 more sources